Loading...
XHKG
8329
Market cap58mUSD
Apr 11, Last price  
0.27HKD
1D
0.00%
1Q
71.97%
Jan 2017
-44.33%
IPO
-19.40%
Name

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Chart & Performance

D1W1MN
P/E
17.66
P/S
0.40
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
4.19%
Revenues
1.04b
-2.18%
20,181,00016,160,00016,310,0003,696,00038,256,000474,652,000530,458,000611,666,000648,268,000721,346,000759,111,000790,286,000867,123,0001,080,871,0001,031,369,000838,805,000986,691,0001,064,861,0001,041,698,000
Net income
25m
+3.68%
-25,967,000-21,167,000-30,595,000-37,476,000-30,104,00021,686,00024,298,00035,855,00033,174,00021,055,00062,692,00050,257,00048,089,00059,719,00036,592,00035,958,00054,346,00024,127,00025,014,000
CFO
0k
-100.00%
5,493,000-32,054,00010,723,00038,934,00063,266,000-63,189,00051,628,00028,991,00039,111,00062,308,00082,854,00055,783,00025,033,00060,352,00093,644,000-69,924,00061,220,00053,686,0000
Earnings
May 26, 2025

Profile

Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products. In addition, the company manufactures herbal medicines and generic drugs products, as well as medical devices. The company is based in Shenzhen, the People's Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
URL
https://www.interlong.com/
IPO date
Sep 12, 2005
Employees
1,453
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,041,698
-2.18%
1,064,861
7.92%
986,691
17.63%
Cost of revenue
1,003,059
1,015,080
909,236
Unusual Expense (Income)
NOPBT
38,639
49,781
77,455
NOPBT Margin
3.71%
4.67%
7.85%
Operating Taxes
15,879
16,148
18,431
Tax Rate
41.10%
32.44%
23.80%
NOPAT
22,760
33,633
59,024
Net income
25,014
3.68%
24,127
-55.60%
54,346
51.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
100,150
85,916
88,209
Long-term debt
8,997
5,612
9,238
Deferred revenue
589
589
Other long-term liabilities
26,283
Net debt
(289,277)
(300,678)
(222,651)
Cash flow
Cash from operating activities
53,686
61,220
CAPEX
(15,214)
(19,714)
Cash from investing activities
60,897
10,757
Cash from financing activities
(32,475)
(9,023)
FCF
5,875
7,224
46,228
Balance
Cash
283,424
382,206
350,098
Long term investments
115,000
10,000
(30,000)
Excess cash
346,339
338,963
270,763
Stockholders' equity
471,255
461,338
638,954
Invested Capital
811,474
767,494
814,770
ROIC
2.88%
4.25%
7.18%
ROCE
3.34%
4.38%
6.97%
EV
Common stock shares outstanding
1,678,000
1,678,000
1,678,000
Price
0.16
-0.61%
0.16
-4.65%
0.17
-7.03%
Market cap
273,514
-0.61%
275,192
-4.65%
288,616
-7.03%
EV
77,153
82,527
375,721
EBITDA
38,639
83,425
113,399
EV/EBITDA
2.00
0.99
3.31
Interest
5,574
7,032
Interest/NOPBT
11.20%
9.08%